このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。英語版ソーステキスト用。

Secondary Bacterial Infections and Nasal Colonization in Scabies and Atopic Dermatitis

2026年9月10日更新者：Tunç Ozen、Istanbul Medeniyet University

Microbiological Profile of Secondary Bacterial Infections and Nasal Colonization in Patients With Scabies and Atopic Dermatitis: A Prospective Observational Study

This prospective observational study will evaluate the microbiological profile of secondary bacterial infection and nasal colonization in participants with scabies or atopic dermatitis. Bacteria isolated from impetiginized skin lesions and nasal swabs will be compared, and antimicrobial susceptibility patterns will be assessed. Healthy participants without an inflammatory skin disease or signs of infection will provide nasal swabs as a control group. Patients will be followed on days 7 and 14 to assess clinical response and related clinical measures.

調査の概要

状態

まだ募集していません

条件

詳細な説明

Participants with dermatologist-confirmed scabies or atopic dermatitis and active impetiginized skin lesions will undergo clinical assessment and microbiological sampling. A superficial swab will be obtained from the infected skin lesion and a nasal swab will be obtained from the nasal vestibules. Healthy controls will undergo nasal sampling only. Cultures will be evaluated for Staphylococcus aureus, Streptococcus pyogenes, and other bacterial isolates. Antimicrobial susceptibility testing will be performed according to European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidance. Skin and nasal isolates will be compared at the species level and by antimicrobial resistance profile. Clinical data include age, sex, disease duration, comorbidities, recent treatments, itch severity using a 0-10 visual analog scale, and lesion morphology, location, number, and excoriation. Patients will be contacted on days 7 and 14 to assess clinical response, new lesion development, change in itch severity, treatment adherence, and local or systemic adverse events.

研究の種類

観察的

入学 (推定)

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

名前：TEST CONTACT - REPLACE
電話番号：+90 000 000 0000
メール：test-contact@example.com

研究場所

トルコ（Türkiye）
- - Istanbul、トルコ（Türkiye）
    - Test Study Site - Replace

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

子
大人
高齢者

健康ボランティアの受け入れ

はい

サンプリング方法

非確率サンプル

調査対象母集団

Participants presenting to a dermatology clinic will include patients with dermatologist-confirmed scabies or atopic dermatitis and active impetiginized skin lesions, as well as healthy controls without inflammatory skin disease or signs of infection.

説明

Inclusion Criteria:

Scabies group: dermatologist-confirmed scabies and an active impetiginized skin lesion.
Atopic dermatitis group: dermatologist-confirmed atopic dermatitis and an active impetiginized skin lesion.
Healthy control group: no inflammatory skin disease or clinical signs of infection.
Written informed consent (and appropriate parent/guardian permission when applicable).

Exclusion Criteria:

Systemic or topical antibiotic use within the previous 14 days.
Active nasal infection or nasal symptoms.
History of nasal surgery or anatomic nasal deformity.

TEST DRAFT NOTE: The source protocol contains wording that may conflict with inclusion of healthy controls; the final eligibility text must be reconciled with the ethics-approved protocol before release.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか？

デザインの詳細

グループ/コホートの数

コホートと介入

グループ/コホート
Scabies with impetiginized lesions Participants with dermatologist-confirmed scabies and an active impetiginized skin lesion suggestive of secondary bacterial infection.
Atopic dermatitis with impetiginized lesions Participants with dermatologist-confirmed atopic dermatitis and an active impetiginized skin lesion suggestive of secondary bacterial infection.
Healthy controls Participants without an inflammatory skin disease or clinical signs of infection; nasal swab sampling only.

この研究は何を測定していますか？

主要な結果の測定

結果測定	メジャーの説明	時間枠
Concordance of bacterial species between impetiginized skin lesion and nasal cultures 時間枠：At baseline (enrollment)	Among participants in the scabies and atopic dermatitis groups with paired evaluable skin and nasal cultures, concordance will be defined as isolation of the same bacterial species from both anatomical sites. Species-level agreement will be summarized and evaluated using Cohen's kappa coefficient.	At baseline (enrollment)

二次結果の測定

結果測定	メジャーの説明	時間枠
Bacterial profile of impetiginized skin lesions 時間枠：At baseline (enrollment)	The number and proportion of lesion cultures yielding Staphylococcus aureus, Streptococcus pyogenes, other bacteria, mixed growth, or no bacterial growth will be summarized.	At baseline (enrollment)
Nasal Staphylococcus aureus carriage across study groups 時間枠：At baseline (enrollment)	The number and proportion of participants with nasal Staphylococcus aureus carriage will be summarized for the scabies, atopic dermatitis, and healthy control groups.	At baseline (enrollment)
Antimicrobial susceptibility and resistance profile of bacterial isolates 時間枠：At baseline (enrollment)	Antimicrobial susceptibility results, including methicillin resistance among Staphylococcus aureus isolates and susceptibility to the antibiotics included in the laboratory panel, will be summarized for skin and nasal isolates.	At baseline (enrollment)
Clinical response at day 14 時間枠：14 days after enrollment	Clinical response will be categorized as complete remission, partial response, no change, or worsening. Associations with bacterial species, methicillin resistance, antimicrobial resistance, nasal carriage, and skin-nasal concordance will be explored.	14 days after enrollment
Development of new skin lesions during follow-up 時間枠：Through 14 days after enrollment	The occurrence of new lesions during the 14-day follow-up period will be recorded.	Through 14 days after enrollment

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

Istanbul Medeniyet University

捜査官

主任研究者：TEST INVESTIGATOR - REPLACE、TEST AFFILIATION - REPLACE

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年10月1日

一次修了 (推定)

2027年3月1日

研究の完了 (推定)

2027年3月1日

試験登録日

最初に提出

2026年9月4日

QC基準を満たした最初の提出物